ELVN
ELVN
US29337E1029
Enliven Therapeutics, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
3B EUR
3.72B EUR
2.39B EUR
915.38M EUR
Enterprise Value
2.08B EUR
3.58B EUR
2.25B EUR
816.88M EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-17.41x
--
--
--
Price to Sales
--
--
--
--
Price to Book
3.35x
4.15x
5.26x
1.99x
EV/Revenue
--
--
--
--
EV/EBITDA
-16.76x
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-1.51%
-1.8%
-2.75%
-5.06%
ende